AEMD

Aethlon Medical, Inc. (AEMD) ESG Analysis Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 4.8 (Moderate)

AEMD appears to have limited disclosed environmental intensity metrics, leaving peer-relative assessment weaker than larger medtech peers with more complete emissions and waste reporting.

The provided zero R&D-to-revenue metric suggests a lighter innovation footprint than peers, which can reduce near-term environmental process complexity but also limits evidence of sustainability-linked product development.

Low leverage relative to many healthcare peers can indirectly support environmental compliance spending, yet it does not by itself indicate stronger operational environmental management.

No material environmental controversies were provided, but the absence of robust public environmental disclosures keeps AEMD below better-disclosing peers on transparency and accountability.

Social

Score:

AEMD’s small-scale profile can support closer stakeholder oversight, but peers with broader clinical footprints typically demonstrate stronger formalized patient-safety and quality systems.

The absence of disclosed workforce, diversity, and training metrics weakens peer-relative confidence in labor practices, even though no adverse social controversy was provided.

Limited evidence of stock-based compensation burden may reduce peer-relative concerns about employee dilution, but it does not establish stronger retention or engagement practices.

No major social incidents were provided, yet sparse disclosure leaves AEMD behind peers that report more consistently on product responsibility and human-capital management.

Governance

Score:

AEMD’s low debt-to-equity ratio suggests less creditor pressure than leveraged peers, which can modestly improve governance flexibility and board oversight discipline.

The net debt-to-EBITDA figure indicates manageable leverage, but peer-relative governance strength remains constrained because capital-allocation and control disclosures are limited.

No evidence of severe governance controversy was provided, yet the lack of detailed disclosure on board independence, audit quality, and shareholder protections weakens relative standing.

Sparse reporting on compensation, related-party risk, and internal controls keeps AEMD below better-governed peers that provide more transparent governance frameworks.

Overall Score

Score:

AEMD ranks as a moderate ESG peer because leverage and controversy risk appear manageable, but limited disclosure across environmental, social, and governance dimensions constrains relative strength.

Score Driver: Limited ESG Disclosure Transparency Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aethlon Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →